{"success":true,"data":{"pressRelease":{"id":"165885","rtpr_id":"nACSFvhCka-20261011","ticker":"AARD","exchange":"NASDAQ","all_tickers":["AARD"],"title":"Recover Investment Losses: Class Action Initiated Against Aardvark Therapeutics, Inc. (AARD)","author":"ACCESSWIRE","published_at":"2026-10-11T11:00:15.888Z","article_body":"NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / October 11,\n2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit\nhas been filed on behalf of investors who purchased or otherwise acquired\nAardvark Therapeutics, Inc. (NASDAQ:AARD) securities.\n\nIf you suffered a loss on your Aardvark Therapeutics, Inc. investment and\nwould like to explore a potential recovery under the federal securities laws,\nLearn about Aardvark Therapeutics, Inc. Class Action (https://pr.report/s9oy)\nor contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call\n(212)363-7500 to speak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: This lawsuit is on behalf of a class consisting of all persons\nand entities that purchased or otherwise acquired: (a) Aardvark common stock\npursuant and/or traceable to the Company's initial public offering conducted\non February 13, 2025; and/or (b) Aardvark securities between February 13, 2025\nand May 14, 2026, both dates inclusive.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (i) ARD-101 was less safe than defendants\nhad led investors to believe; (ii) accordingly, ARD-101's clinical,\nregulatory, and commercial prospects were overstated; and (iii) as a result,\nthe offering documents were materially false and/or misleading and failed to\nstate information required to be stated therein.\n\nWHAT'S NEXT? If you purchased Aardvark Therapeutics, Inc. stock during the\nrelevant time frame - even if you still hold your shares, learn about your\nrights to seek a recovery (https://pr.report/s9oz). There is no cost or\nobligation to participate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/recover-investment-losses-class-action-initiated-against-aardvar-1235500)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSFvhCka-20261011","title":"Recover Investment Losses: Class Action Initiated Against Aardvark Therapeutics, Inc. (AARD)","author":"ACCESSWIRE","ticker":"AARD","created":"2026-10-11T11:00:15.888Z","tickers":["AARD"],"exchange":"NASDAQ","article_body":"NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / October 11,\n2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit\nhas been filed on behalf of investors who purchased or otherwise acquired\nAardvark Therapeutics, Inc. (NASDAQ:AARD) securities.\n\nIf you suffered a loss on your Aardvark Therapeutics, Inc. investment and\nwould like to explore a potential recovery under the federal securities laws,\nLearn about Aardvark Therapeutics, Inc. Class Action (https://pr.report/s9oy)\nor contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call\n(212)363-7500 to speak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: This lawsuit is on behalf of a class consisting of all persons\nand entities that purchased or otherwise acquired: (a) Aardvark common stock\npursuant and/or traceable to the Company's initial public offering conducted\non February 13, 2025; and/or (b) Aardvark securities between February 13, 2025\nand May 14, 2026, both dates inclusive.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (i) ARD-101 was less safe than defendants\nhad led investors to believe; (ii) accordingly, ARD-101's clinical,\nregulatory, and commercial prospects were overstated; and (iii) as a result,\nthe offering documents were materially false and/or misleading and failed to\nstate information required to be stated therein.\n\nWHAT'S NEXT? If you purchased Aardvark Therapeutics, Inc. stock during the\nrelevant time frame - even if you still hold your shares, learn about your\nrights to seek a recovery (https://pr.report/s9oz). There is no cost or\nobligation to participate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/recover-investment-losses-class-action-initiated-against-aardvar-1235500)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-11T11:00:15.953373958Z","server_sent_at_ms":1791716415953},"received_at":"2026-10-11T11:00:16.019Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/recover-investment-losses-class-action-initiated-against-aardvar-1235500"},"analysis":{"id":"154268","press_release_id":"165885","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Securities class action alleges misleading safety/prospect disclosures around ARD-101 and the February 2025 IPO"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced a securities class action filed on behalf of Aardvark Therapeutics (AARD) investors covering the February 13, 2025 IPO and purchases through May 14, 2026.\n\nThe complaint alleges ARD-101 was less safe than represented and that clinical, regulatory, and commercial prospects were overstated.\n\nThe release is primarily a law-firm solicitation seeking lead plaintiffs; no new issuer disclosure or court ruling is included.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm class-action solicitation against AARD -- suppress; monitor only for certified class or settlement."},"keyFigures":{},"quotedText":"(i) ARD-101 was less safe than defendants\nhad led investors to believe; (ii) accordingly, ARD-101's clinical,\nregulatory, and commercial prospects were overstated","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Levi & Korsinsky contact attorney"},{"name":"Ed Korsinsky, Esq.","role":"Levi & Korsinsky"}],"products":["ARD-101"],"companies":[{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"class action target/issuer"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Levi & Korsinsky announcing a securities class action and soliciting lead plaintiffs. No certified class or settlement; boilerplate solicitation language throughout."},"tickerRelevance":{"others":[],"primary":"AARD"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap-biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky announced a securities class action filed on behalf of Aardvark Therapeutics (AARD) investors covering the February 13, 2025 IPO and purchases through May 14, 2026.\n\nThe complaint alleges ARD-101 was less safe than represented and that clinical, regulatory, and commercial prospects were overstated.\n\nThe release is primarily a law-firm solicitation seeking lead plaintiffs; no new issuer disclosure or court ruling is included.","key_figures":{},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Levi & Korsinsky contact attorney"},{"name":"Ed Korsinsky, Esq.","role":"Levi & Korsinsky"}],"products":["ARD-101"],"companies":[{"name":"Aardvark Therapeutics, Inc.","ticker":"AARD","relationship":"class action target/issuer"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-11T11:00:20.124Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap-biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4080,"modelName":"glm-5.3-flashx"}}